Skip to content

Oral Versus Intravenous Fluid Therapy in the Emergency Department

Oral Versus Intravenous Fluid Therapy in the Emergency Department

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07361952
Acronym
OVID-B
Enrollment
250
Registered
2026-01-23
Start date
2025-10-03
Completion date
2026-07-01
Last updated
2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fluid Management

Keywords

oral fluids, Emergency department, intravenous fluids, fluid management

Brief summary

The goal of this randomized clinical feasibility trial is to determine whether oral fluid therapy can achieve prescribed fluid volumes as effectively as intravenous fluid therapy in adult patients admitted to the emergency department who require fluid treatment. The main questions it aims to answer are: Are patients receiving oral fluids equally likely to achieve the prescribed fluid volume compared with patients receiving intravenous fluids? Is it feasible to conduct a randomized trial of oral versus intravenous fluid therapy in the emergency department, based on recruitment rate and protocol adherence? Researchers will compare oral tap water administration with standard intravenous crystalloid therapy to assess whether oral fluids are non-inferior in achieving prescribed fluid volumes and to evaluate feasibility outcomes. Participants will: Be randomized to receive either oral tap water or intravenous crystalloid fluids during their stay in the emergency department Receive a fluid volume and administration rate determined by the treating physician Be monitored according to standard clinical practice during the emergency department stay Have fluid intake, vital signs, and clinical outcomes recorded, with follow-up through routine health records up to 30 days after inclusion

Interventions

Any fluid volume prescribed by the physician during the ED stay is administered orally.

Any fluid volume prescribed by the physician during the ED stay is administered intravenously.

Sponsors

Esbjerg Hospital - University Hospital of Southern Denmark
Lead SponsorOTHER
Odense University Hospital
CollaboratorOTHER
Hospital of Southern Jutland, Aabenraa, Denmark
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 or above * At least 1000 ml of crystalloid fluid therapy prescribed by the physician

Exclusion criteria

* Altered mental state prohibiting oral fluid intake (Glasgow Coma Scale ≤ 12) * Pregnancy * Oral fluids contraindicated (e.g. bowel obstruction) * Severe hyponatremia (sodium \<120 mEq/L) * Requiring treatment in the intensive care unit

Design outcomes

Primary

MeasureTime frame
Percentage of patients achieving the fluid volume prescribed during the first 48 hours in the emergency departmentFrom inclusion until end of participation. End of participation is defined as the timepoint of leaving the emergency department or after 48 hours, whichever happens first.

Secondary

MeasureTime frameDescription
Fluids received in the ED (ml)From inclusion to end of participation (defined as ED stay or maximum of 48 hours), unless mentioned otherwiseIntravenous fluids, oral fluids, total fluids
Fluids received in the ED after inclusion in the study (ml)From inclusion to end of participation (defined as ED stay or maximum of 48 hours), unless mentioned otherwiseIntravenous fluids, oral fluids, total fluids
Change in systolic and mean arterial pressure at 8 hours or discharge, whatever comes first.8 hours or discharge, whatever comes first.
Hospital-free days alive at 30 days (counting up to the day the patient deceased if applicable)30 days
Mortality at 30 days30 days
Number of hours with a peripheral intravenous catheterFrom inclusion to end of participation (defined as ED stay or maximum of 48 hours), unless mentioned otherwise

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026